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The adverse impact of low socioeconomic status on the
access to care, treatment, and outcomes of nonmalignant [1]
and malignant diseases [2,3] has been well recognized. This
effect hasn’t been explored with allogeneic stem cell trans-
plantation for myeloid leukemias.
We attempted to illuminate such an effect by complet-
ing a retrospective analysis of all patients with AML-CR1 (n =
30) or CML-CP1 (n = 29) that received 6 antigen-matched
sibling donor marrow transplants at the University of Okla-
homa from June 1986 through June 1998. Minimum follow-
up was 16 months (range, 16-167 months). We used the
type of insurance coverage as a surrogate for socioeconomic
status and denoted patients with commercial or Medicare
coverage as insured/non-poor and patients with Medicaid or
no insurance as under-insured/poor. Patient characteristics
and outcomes are displayed in Table 1. Differences in sur-
vival times (censoring patients who are still alive) between
the insured and uninsured as measured by the log-rank test
were statistically different (P = .03). Mortality at <30, 30-99,
and ≥100 days to 16 months (follow-up achieved on all
patients) was examined and differences were seen only at
≥100 days to 16 months.
At diagnosis, the under-insured/poor group did not have
an excess of poor-prognostic findings such as unfavorable
cytogenetics, leukocytosis, or CNS involvement. Their time
from diagnosis to transplantation was the same as the
insured/non-poor. There was no difference in the rate of
interferon use. There was no difference in survival between
Caucasian and non-Caucasian patients.
The under-insured/poor were 10 years younger, suf-
fered no Grade II-IV acute GVHD, less extensive chronic
GVHD, yet had worse survival after day +30 that became
statistically signiﬁcant at 100 days posttransplantation.
We believe this phenomenon of delayed mortality likely
represents the under-insured/poor patients’ inability to
comply with or seek medical care because of deficient
socioeconomic resources. During the early posttransplanta-
tion period, when the under-insured/poor patients are in
hospital, the resources of a comprehensive Health Sciences
Center can compensate for their socioeconomic deﬁciency
but an increased risk of death occurs after they return to
their pretransplantation social setting.
We propose that these preliminary but provocative ﬁnd-
ings be further investigated utilizing demographic data from
the IBMTR/ABMTR registries. If our conclusions are veri-
fied, there could be profound implications for the public
funding of stem cell transplantation. In addition, socioeco-
nomic status would join other established prognostic factors
describing “high-risk” patients that are relevant to the
reporting of institution-speciﬁc outcome results.
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Table I. Patient Characteristics and Outcome
Insured/ Under-insured/
Non-poor Poor
(n = 45) (n = 14) P
Age, y (mean ±SD) 36.8 ±11.8 27.0 ±16.3 .017*
Non-Caucasian 18% (8/45) 43% (6/14) .075†
Diagnosis AML 49% (22/45) 57% (8/14) .590‡
BMT year .467†
86-90 16 (36%) 3 (21%)
91-95 17 (38%) 8 (57%)
>95 12 (27%) 3 (21%)
AC GVHD grade III-IV 16% (7/45) 0% (0/14) .181†
Extensive chronic GVHD 39% (16/41) 30% (3/10) .462†
Mortality <30 day 2% (1/45) 7% (1/14) .421†
Mortality 30-99 days 7% (3/44) 23% (3/13) .125†
Mortality 100 days 15% (6/41) 50% (5/10) .027† 
to <16 months
*Independent t test.
†The Fisher exact test.
‡Chi-square test.
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